With $6 billion left in firepower, Pfizer is planning transactions in the hundreds of millions to the low-billions range, ...

In a post-Metsera world, Structure Therapeutics could be the next big takeover candidate, analysts said Tuesday.

Propelled by a flurry of dealmaking late in the year, M&As in 2025 ended on a strong note, with high activity expected to ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

The deal focuses on a weight-loss pill in development at YaoPharma, a GLP-1 agonist codenamed YP05002, which is currently in ...

(Reuters) -Shares of Metsera fell over 15% in early trading on Monday, after the weight-loss drug developer accepted a sweetened offer from Pfizer to end a fierce bidding war between the pharma giant ...

Pfizer has entered into a global collaboration and license agreement with YaoPharma for the development, manufacturing and commercialization of YP05002, a small-molecule GLP-1 receptor agonist ...

Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, ...

Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million in value and announced this year. M&A, however, has not been enough for ...

Metsera was the target of a bidding war by pharma giants. The company has an innovative obesity drug candidate. 10 stocks we like better than Metsera › Innovative biopharmaceutical company Metsera ...

Dec 12 (Reuters) - The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative ...